Thyroid Cancer clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 16 years and up
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy.
Sacramento, California and other locations